复方苦参注射液联合含铂双药化疗方案治疗晚期肺腺癌患者的疗效观察  

Efficacy of Compound Kushen Injection Combined with Platinum-Containing Dual-Drug Chemotherapy in Patients with Advanced Lung Adenocarcinoma

作　　者：林雁 朱杰 高鹏[1] 李迅[1] LIN Yan;ZHU Jie;GAO Peng;LI Xun(Dept.of Respiratory Medicine,Chuzhou First People’s Hospital,Anhui Chuzhou 341100,China)

机构地区：[1]滁州市第一人民医院呼吸内科,安徽滁州341100

出　　处：《中国医院用药评价与分析》2025年第1期72-75,共4页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨复方苦参注射液联合含铂双药化疗方案治疗晚期肺腺癌的疗效及对肿瘤标志物水平、化疗不良反应的影响。方法:采用回顾性研究,依据不同的治疗方案,将2020年1月至2023年1月于该院接受治疗的100例晚期肺腺癌患者分为观察组(51例)和对照组(49例)。对照组患者采用AP方案(培美曲塞+卡铂)化疗;观察组患者在对照组的基础上静脉滴注复方苦参注射液,1日1次,持续治疗10 d。比较两组患者的疗效、肿瘤标志物水平和不良反应发生情况。结果:治疗后,观察组患者的客观缓解率[54.90%(28/51)vs.30.61%(15/49)]和疾病控制率[80.39%(41/51)vs.59.18%(29/49)]明显高于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组卡诺夫斯凯计分改善+稳定患者的占比明显高于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者神经元特异性烯醇化酶、癌胚抗原水平较治疗前降低,且观察组低于对照组,差异均有统计学意义(P<0.05)。治疗期间,观察组患者骨髓抑制、肾功能损伤和胃肠道反应等不良反应发生率低于对照组,差异均有统计学意义(P<0.05)。结论:复方苦参注射液联合含铂双药化疗方案可提高肺腺癌患者的临床治疗效果,降低肿瘤标志物水平,减少不良反应发生。OBJECTIVE:To probe into the efficacy of compound Kushen injection combined with platinum-containing dual-drug chemotherapy in patients with advanced lung adenocarcinoma and its effects on tumor marker levels and adverse drug reactions of chemotherapy.METHODS:Retrospective study was performed,100 patients with advanced lung adenocarcinoma treated in the hospital from Jan.2020 to Jan.2023 were divided into into the observation group(51 cases)and control group(49 cases)according to different treatment regimens.The control group was treated with AP(pemetrexed+carboplatin)chemotherapy regimen,while the observation group received intravenous infusion of compound Kushen injection(once a day)on the basis of the control group,both groups were treated for 10 d.The efficacy,level of tumor markers and occurrence of adverse drug reactions were compared between two groups.RESULTS:After treatment,the objective remission rate[54.90%(28/51)vs.30.61%(15/49)]and disease control rate[80.39%(41/51)vs.59.18%(29/49)]in the observation group were significantly higher than those in the control group,with statistically significant differences(P<0.05).After treatment,the proportion of Kanofsky performance score improvement+stability in the observation group was significantly higher than that in the control group,the difference was statistically significant(P<0.05).After treatment,the levels of neuron-specific enolase and carcinoembryonic antigen in two groups were lower than those before treatment,and the observation group was significantly lower than the control group,with statistically significant differences(P<0.05).During the treatment,the incidence of myelosuppression,renal function injury and gastrointestinal reactions in the observation group was lower than that in control group,with statistically significant differences(P<0.05).CONCLUSIONS:Compound Kushen injection combined with platinum-containing dual-drug chemotherapy can improve the clinical treatment effects of patients with lung adenocarcinoma,reduce the level of tumor marker

关 键 词：复方苦参注射液 肺腺癌 临床治疗效果 不良反应 

分 类 号：R979.1[医药卫生—药品]